Matrix metalloproteinase polymorphisms and HIV anti-retroviral drugs: New implications of pharmacogenomics in therapeutic approaches

Pharmacogenomics Journal

Volumn 9, Issue 6, 2009, Pages 355-357

  Mannello, F ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; GELATINASE B; LAMIVUDINE; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; DRUG TREATMENT FAILURE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; GLIA CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN SECRETION; SINGLE NUCLEOTIDE POLYMORPHISM;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HUMANS; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 73949143487     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.35     Document Type: Note

References (15)

1. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-1701.
2. Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005; 10: 19-24.
3. Visse R, Nagase H. Matrix metalloprotei-nases and tissue inhibitors of metalloprotei-nases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
4. Mannello F, Tonti G, Bagnara GP, Papa S. Role and function of matrix metalloprotei-nases in the differentiation and biological characterization of mesenchymal stem cell. Stem Cells 2006; 24: 475-481.
5. Brinckerhoff CE, Matrisian LM. Matrix me-talloproteinases: a tail of a frog that became a prince. Nature 2002; 3: 207-214.
6. Mannello F, Tonti G, Papa S. Matrix metal-loproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Target 2005; 5: 285-298.
7. Elkington PTG, O'Kane CM, Friedland JS. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005; 142: 12-20.
8. Webster NL, Crowe SM. Matrix metallopro-teinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leuk Biol 2006; 80: 1052-1066.
9. Mastroianni CM, Liuzzi GM. Matrix metallo-proteinase dysregulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 2007; 13: 449-459.
10. Mannello F. Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon? Recent Patent Drug Discov 2006; 1: 91-103.
11. Mannello F, Tonti GA. Statins and breast cancer: may matrix metalloproteinase be the missing link? Cancer Invest 2009; 27: 466-470.
12. Latronico T, Liuzzi GM, Riccio P, Lichtner M, Mengoni F, D'Agostino C et al. Antiretroviral therapy inhibits matrix metalloproteinase-9 from mononuclear cells of HIV-infected patients. AIDS 2007; 21: 677-684.
13. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol 2007; 7: 333-342.
14. Mahungu TW, Johnson MA, Owen A, Back DJ. The impact of pharmacogenetics on HIV therapy. Int J STD AIDS 2009; 20: 145-151.
15. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Machado AA, Tanus-Santos JE. A matrix metalloproteinase 9 (MMP-9) polymorphism affects highly active anti-retroviral therapy-induced changes in qcir-culating MMP-9 levels in HIV patients. Pharmacogenomics J 2009; 9: 265-273.